Genomma Lab Internacional SAB de CV Class B

As of June 30, 2026, Genomma Lab Internacional SAB de CV Class B carries a market capitalization of 14.66B, placing it among publicly traded companies globally. Its enterprise value stands at 19.99B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Genomma Lab Internacional SAB de CV Class B's next confirmed earnings release is scheduled for February 24, 2027.

As of June 30, 2026, Genomma Lab Internacional SAB de CV Class B has 977.75M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Genomma Lab Internacional SAB de CV Class B maintains a current ratio of 1.84, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Genomma Lab Internacional SAB de CV Class B recorded 558.12M in income tax expense.

As of the close on October 22, 2026, Genomma Lab Internacional SAB de CV Class B's stock has declined approximately 14.19% over the past 52 weeks. The 50-day moving average sits at 13.18, while the 200-day moving average is 15.60.

As of June 30, 2026, Genomma Lab Internacional SAB de CV Class B holds 2.44B in cash and equivalents against 7.77B in total debt, resulting in a net debt position of 2.13B. Total book value stands at 11.78B, with working capital of 6.01B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Genomma Lab Internacional SAB de CV Class B paid dividends of 0.60 per share.

Genomma Lab Internacional SAB de CV Class B's most recent stock split took place on August 3, 2010 with a 1:2 split ratio.